Physician profile

Daniel Hoffman

Urology · Fredericksburg, VA

NPI 1225085657

$7,805.67

in general payments reported to CMS, 2019-2025

46 companies · $124 in 2025

The $124 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,610.29
Education$35.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $2,642.51 2019-2024 Rezum Generator
Janssen Biotech, INC. $842.03 2019-2024 Erleada
Astellas Pharma US INC $807.26 2019-2024 Xtandi, Myrbetriq
Dendreon Pharmaceuticals LLC $555.94 2019-2023 Provenge
Pfizer INC. $536.17 2019-2024
Blue Earth Diagnostics $198.99 2021-2023
Bayer Healthcare Pharmaceuticals INC. $182.67 2021-2024
Urogen Pharma, INC. $154.90 2020-2024 Jelmyto
Axonics, INC. $114.04 2022-2024 Axonics
Progenics Pharmaceuticals, INC. $113.71 2022-2024 Pylarify
Bioprotect Medical, INC. $111.31 2024-2025 Bioprotect Balloon Implant System
Teleflex LLC $106.08 2021-2022
Amgen INC. $104.60 2019-2024 Evenity, Prolia
Myriad Genetic Laboratories, INC. $104.21 2021-2024 Prolaris
Accord Healthcare, INC. $98.73 2022-2023
Show all 46 companies
CompanyGeneral paymentsYearsTop products
Merck Sharp & Dohme LLC $93.62 2020-2024 Lynparza, Keytruda, Welireg
Myovant Sciences INC. $87.97 2021-2022
Sun Pharmaceutical Industries INC. $80.39 2021-2023 Yonsa
Olympus America INC. $73.44 2021-2024 Soltive
Tolmar Pharmaceuticals, INC. $70.36 2019-2021
Astrazeneca Pharmaceuticals Lp $53.77 2020-2025 Imfinzi
Antares Pharma, INC. $53.27 2020-2022
Alnylam Pharmaceuticals INC. $50.72 2021
Photocure INC $47.70 2021-2022
Endo Pharmaceuticals INC. $43.77 2019
Allergan, INC. $39.16 2019
Novartis Pharmaceuticals Corporation $36.51 2022-2023
Ferring Pharmaceuticals INC. $33.55 2019-2024 Adstiladrin
Abbvie INC. $32.02 2020-2022
Coloplast Corp $31.67 2023 Speedicath
Tempus Ai, INC $28.82 2024
Sumitomo Pharma America, INC. $28.55 2024 Gemtesa
Rochester Medical Corporation $25.64 2019-2020
Agiliti Surgical, INC. $23.64 2019
Ambu INC. $23.22 2021
Tolmar, INC. $22.79 2023
Genzyme Corporation $20.91 2023
Travere Therapeutics, INC. $17.45 2019
Acerus Pharmaceuticals Corporation $16.76 2020
Ethicon US, LLC $15.38 2022
Verity Pharmaceuticals INC. $14.98 2023 Trelstar
Takeda Pharmaceuticals U.S.A., INC. $14.09 2023 Gattex
Procept Biorobotics Corporation $13.68 2024 Aquabeam System
Pacira Pharmaceuticals Incorporated $13.39 2020
Mission Pharmacal Company $13.22 2019
Smith+Nephew, INC. $12.08 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel Hoffman

$7,805.67

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $124 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).

https://glasscript.com/doctor/146569/daniel-hoffman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.